STEP III: economic - budgetary impact analysis
This phase entails looking at the impact of the use of the agents in a therapeutic class on the complete healthcare economy, in both primary and secondary care. Reduced medicine costs are the result of the fact that, of all the products that meet the evidence and safety as outlined, the most cost effective are selected to deliver the desired outcomes at minimized cost to the health service.
Information services / support
- Reports of previous budgetary impact analysis
- Methodology used for comparative purposes in both primary and secondary care
- Consultancy: how previous budgetary impact analyses were carried out and how they can be re-applied in any specific setting.